Skip to main content
8044 Suchergebnisse für:

Ritonavir 

sortieren nach |
"Aktualität" sortiert die Ergebnisse nach Publikationsdatum. "Relevanz" berücksichtigt auch noch andere Faktoren wie zum Beispiel die Häufigkeit der Suchbegriffe im Text.
  1. Open Access 12.04.2024 | Online First

    Ritonavir: 25 Years’ Experience of Concomitant Medication Management. A Narrative Review

    Ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme and is commonly used as a pharmacokinetic (PK) enhancer in antiviral therapies because it increases bioavailability of concomitantly administered antivirals. Decades of experience …

  2. 10.04.2024 | Online First

    Prevalence and Management of Medication Interactions with Nirmatrelvir-Ritonavir at a Large Urban Academic Medical Center: An Observational Study

    Nirmatrelvir-ritonavir received emergency use authorization by the U.S. Food and Drug Administration in December 2021 to treat ambulatory patients diagnosed with COVID-19 at risk of developing severe disease. 1 Ritonavir is an inhibitor of hepatic …

  3. Open Access 01.12.2024 | OriginalPaper

    A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient

    The outcomes of lung transplant recipients infected with coronavirus disease 2019.

  4. 08.03.2024 | Online First

    Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment

    Docetaxel is a taxane chemotherapeutic agent that is widely used in the clinic as single agent or in combination with other cytotoxic drugs for the treatment of a broad range of cancers, such as breast cancer, non-small cell lung cancer and …

  5. 11.03.2024 | Online First

    The Impacts of Nirmatrelvir–Ritonavir on Myocardial Injury and Long-Term Cardiovascular Outcomes in Hospitalized Patients with COVID-19 amid the Omicron Wave of the Pandemic

    Although the pathogenicity and clinical severity of omicron COVID-19 appear to be weakened compared with previous variants, it tends to evolve toward more transmissible, and the number of hospital admissions and cardiovascular complications might …

  6. 01.12.2024 | OriginalPaper

    Red light-emitting diode therapy minimizes the functional deleterious effects of the antiretroviral ritonavir on osteoblasts in vitro

    Acquired immune deficiency syndrome (AIDS) is a serious public health issue worldwide [ 1 ]. Among the various medical concerns that HIV-positive patients face, stands out the high rates of impaired skeletal mineralization, clinically represented …

  7. Open Access 01.12.2024 | OriginalPaper

    Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study

    In the context of the deadly COVID-19 pandemic, various developed or repurposed oral antiviral medications have been authorized for emergency use to treat SARS-CoV-2 infection [ 1 , 2 ]. Nirmatrelvir-ritonavir and azvudine are the main antivirus …

  8. 22.01.2024 | Online First

    Nirmatrelvir-ritonavir (Paxlovid) Access, Use, and Eligibility Among Adults with COVID-19 in Los Angeles County: The LA Pandemic Surveillance Cohort Study

    Nirmatrelvir-ritonavir (Paxlovid), an effective treatment for COVID-19, was approved for emergency use authorization (EUA) in December 2021, for individuals at high risk of developing severe COVID-19. 1 Nirmatrelvir-ritonavir has been shown to …

  9. Open Access 23.02.2024 | Online First

    Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers

    The COVID-19 pandemic affects people worldwide and can lead to hospitalization and death. Nirmatrelvir-ritonavir (Paxlovid ® ) has been available through an Emergency Use Authorization (EUA) since early 2022 and was approved by the US Food and Drug …

  10. Open Access 19.12.2023 | Online First

    Influence of a Short Course of Ritonavir Used as Booster in Antiviral Therapies Against SARS-CoV-2 on the Exposure of Atorvastatin and Rosuvastatin

    Nirmatrelvir/ritonavir (Paxlovid®) was approved in January 2022 for the early treatment of SARS-CoV-2-infected patients at high risk of severe courses. Its component ritonavir is used as a boosting agent to reach and maintain therapeutic drug …

  11. 01.07.2023 | News

    Ritonavir/tacrolimus

    Drug level increased following interaction: case report
  12. Open Access 24.07.2023 | OriginalPaper

    Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study

    This article is published with digital features, including a graphical abstract, to facilitate understanding of the article. To view digital features for this article, go to https://doi.org/10.6084/m9.figshare.23608389 .

  13. Open Access 01.12.2023 | OriginalPaper

    Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient

    The prevalence of chronic and end-stage kidney disease in people living with HIV (PLWH) is increasing with the improved life expectancy and the related aging of the HIV population [ 1 , 2 ]. As a consequence, kidney transplantation is increasingly …

  14. Open Access 01.12.2023 | OriginalPaper

    Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study

    The use of antiretroviral therapy (ART) in people living with human immunodeficiency virus (PLHIV) has evidently reduced opportunistic infection-related morbidity and mortality [ 1 ]. Despite undetectable plasma viral load, immune activation and …

  15. 01.02.2023 | ReviewPaper

    Nirmatrelvir plus ritonavir in COVID-19: a profile of its use

    Oral nirmatrelvir plus ritonavir (Paxlovid™) is an effective treatment option for coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nirmatrelvir inhibits the main protease of …

  16. Open Access 01.06.2022 | Erratum

    Correction to: Nirmatrelvir Plus Ritonavir: First Approval

    The article Nirmatrelvir Plus Ritonavir: First Approval, written by Yvette N. Lamb, was originally published electronically in SpringerLink on 19 March 2022 without open access. After publication in volume 82, issue 5, pages 585–591, Pfizer Inc.

  17. Open Access 01.04.2022 | ReviewPaper

    Nirmatrelvir Plus Ritonavir: First Approval

    Nirmatrelvir plus ritonavir (Paxlovid™; Pfizer) is a co-packaged combination of nirmatrelvir and ritonavir tablets, intended for co-administration and developed for the treatment and post-exposure prophylaxis of coronavirus disease 2019 …

  18. 01.12.2021 | News

    Ritonavir/tacrolimus interaction

    Various toxicities: case report
  19. 01.04.2022 | News

    Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19?

  20. 15.06.2020 | Ritonavir | ReviewPaper
    Schwere COVID-19-Infektion

    Lopinavir-Ritonavir-Kombination nicht wirksam

    Derzeit wird eine Vielzahl von Studien mit Medikamenten durchgeführt, die in vitro eine Inhibition des neuen Coronavirus bewirken. Die Ergebnisse einer Studie zur Wirksamkeit der Kombi von Lopinavir und Ritonavir bei COVID-19 sind nicht gerade ermutigend, aber das könnte sich noch ändern.

Suchergebnisse filtern:

e.Medpedia

Orale Applikation von antineoplastischen Substanzen in der Tumortherapie

Die Urologie
Neben der stets größer werdenden Gruppe der Tyrosinkinase-Inhibitoren zur Therapie des metastasierten Nierenzellkarzinoms werden in diesem Kapitel die Anwendung von Bicalutamid, die Gruppe der „neuen“ oralen Hormontherapien sowie Olaparib als erster Vertreter der Wirkstoffklasse der PARP-Inhibitoren beim Prostatakarzinom beschrieben. Neben der immer komplexer werdenden Indikationsstellung stellt die Durchführung der Supportivtherapie hohe Anforderungen an Patient und Behandler.

weitere e.Medpedia Einträge

Suchoperatoren:

„ ... ... “ Findet Dokumente mit genau dieser Wortgruppe in exakt dieser Schreibweise und Reihenfolge (z.B., "rheumatische Beschwerden").
AND / UND Findet Dokumente, in denen beide Begriffe zusammen vorkommen (z.B., alkohol UND demenz).
OR / ODER Findet Dokumente, in denen einer der beiden oder beide Begriffe vorkommen (z.B., hiv ODER aids).
Leerzeichen Findet Dokumente, in denen alle Begriffe vorkommen. Der Leerschritt wird als UND interpretiert (z.B., isolierte systolische hypertonie).
NOT / NICHT Findet Dokumente, in denen der Begriff nach NOT nicht vorkommt (z.B., sars NOT sars-cov-2).
COUNT(...)>n Findet Dokumente, in denen der gesuchte Begriff mehr als n mal vorkommt. n steht für eine beliebige Anzahl (z.B., COUNT(mammakarzinom)>8).
NEAR(..., ..., ) Findet Dokumente, in denen beide Begriffe in beliebiger Reihenfolge innerhalb von maximal n Worten zueinander stehen. Empfehlung: wählen Sie zwischen 15 und 30 als maximale Wortanzahl (z.B., NEAR(covid, diabetes,20)).
* Findet Dokumente, in denen der Begriff in Wortvarianten vorkommt, wobei diese VOR, HINTER oder VOR und HINTER dem Suchbegriff anschließen können (z.B., thrombose*, *thrombose, *thrombose*).
? Findet Dokumente mit dem Suchbegriff in verschiedenen Schreibweisen, hier mit s oder z, also organisation und organization. Das ? steht für eine einzige Stelle (z.B., organi?ation).
& + - Sonderzeichen werden als UND interpretiert (z.B., Diagnose + Therapie).

Sie können Operatoren mit Ihrer Suchanfrage kombinieren, um diese noch präziser einzugrenzen.

Fahren Sie mit der Maus über den Suchoperator, um eine Erklärung seiner Funktionsweise anzuzeigen.